Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
clinical trials
Pharma
Argenx cans Vyvgart trials in thyroid eye disease over futility
Argenx is discontinuing its late-stage UplighTED studies of subcutaneous efgartigimod in adults with moderate to severe thyroid eye disease.
Fraiser Kansteiner
Dec 15, 2025 10:00am
FDA official chastises Aurinia med in now-deleted LinkedIn post
Sep 30, 2025 10:15am
Fierce Biotech
Lilly's oral GLP-1 charts 10.5% weight loss in diabetic patients
Aug 26, 2025 6:45am
InflaRx scraps vilobelimab study in rare skin disorder
May 28, 2025 9:55am
Fierce's forecasts for the next year in biopharma
Jan 17, 2025 8:45am
More testing needed after Moderna trial halted by FDA: experts
Dec 13, 2024 8:15am
